MYK-491

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Heart Failure With Reduced Ejection Fraction

Drug Information

Target Indication

Heart Failure With Reduced Ejection Fraction

Clinical Trial

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

CELG-RI

BRISTOL MYERS SQUIBB CO

Related Pipeline

HIV Infections

Cardiomyopathy, Hypertrophic

Squamous Cell Carcinoma of the Head and Neck

HIV

Rheumatoid Arthritis